Cash, cash equivalents and restricted cash as of June 30, 2025 was $162.1 million and is expected to support planned operations, including completion of the ongoing Phase 3 AURORA trial for Descartes-08 in MG, into mid-2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics announces new employment inducement grants
- Cartesian Therapeutics Advances mRNA CAR T-cell Therapy for Myasthenia Gravis
- Wedbush bullish on Cartesian Therapeutics, initiates with an Outperform
- Cartesian Therapeutics initiated with an Outperform at Wedbush
- Cartesian Therapeutics Holds Annual Stockholders Meeting